Name: Allergan PLC (NYSE:AGN) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Revenues as Reported

Revenues as Reported

Download chart

Allergan PLC, income statement, revenues

US$ in thousands

12 months ended:	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
US Specialized Therapeutics	6,820,000)	6,920,300)	6,803,600)	5,811,700)	4,309,800)
US General Medicine	5,834,900)	5,322,900)	5,796,200)	5,923,900)	6,338,400)
International	3,402,000)	3,504,700)	3,319,500)	2,881,300)	2,187,300)
Anda Distribution	—)	—)	—)	—)	2,225,400)
Segment revenues	16,056,900)	15,747,900)	15,919,300)	14,616,900)	15,060,900)
Corporate revenues	32,000)	39,500)	21,400)	(46,300)	10,100)
Net revenues	16,088,900)	15,787,400)	15,940,700)	14,570,600)	15,071,000)

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

Net revenues exhibited a period of volatility followed by modest growth between 2015 and 2019. After a decline from $15.07 billion in 2015 to $14.57 billion in 2016, the total revenue recovered and climbed to $16.09 billion by the end of 2019. This overall trajectory indicates a net increase of approximately 6.7% over the five-year period, characterized by a stabilization of revenue streams after significant structural changes in the early part of the period.

US Specialized Therapeutics Growth: This segment demonstrated the most consistent and substantial growth, increasing from $4.31 billion in 2015 to a peak of $6.92 billion in 2018. Although a slight contraction to $6.82 billion occurred in 2019, the segment remains a primary driver of total revenue expansion, reflecting a strong upward trend in specialized market penetration.
US General Medicine Volatility: A downward trend was observed in the US General Medicine segment for the majority of the analyzed period. Revenues declined steadily from $6.34 billion in 2015 to a low of $5.32 billion in 2018. However, a recovery was noted in 2019, with revenues increasing to $5.83 billion, suggesting a potential stabilization or a shift in product performance.
International Market Expansion: International revenues showed a consistent growth pattern, rising from $2.19 billion in 2015 to $3.40 billion in 2019. The steady increase through 2018 indicates successful geographic diversification and an expanding global footprint, although a slight decrease was recorded in the final year.
Structural Segment Shifts: A significant structural change is evident regarding Anda Distribution, which contributed $2.23 billion in 2015 but ceased to contribute to the revenue stream from 2016 onward. This absence indicates a complete divestiture or strategic reorganization of the distribution business.
Corporate Revenue Impact: Corporate revenues remained immaterial relative to total net revenues, fluctuating between a low of negative $46.3 million in 2016 and a high of $39.5 million in 2018. These figures had a negligible impact on the overall financial trajectory of the organization.

AI Ask an analyst for more

My previous chats

Add tokens

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?